NASH MARKET FORECAST FOR COMPLEMENTARY TREATMENTS (Q)


The second peak in graph could seems curious, but in fact, it is because of apparition of new drugs with less adverse effects on lipids, wich enlarge the new market segment of patients with CV risk. 


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE